AMT-130 AAV5-miHTT Updated Jul 2
The BLA submission in Q3 2026 is the key near-term catalyst. The FDA has already aligned on the submission package, but final acceptance and review timelines remain to be seen. Watch for the official BLA filing announcement, PDUFA date assignment, and any FDA Advisory Committee meeting. The $225M June 2026 offering funds commercialization readiness but added ~8% dilution. Analysts are bullish (16 buy vs 5 hold, mean PT ~$64.59, ~47% upside from ~$44).
- First disease-modifying therapy for Huntington's disease, massive unmet need with no approved treatments that slow progression
- High-dose showed 75% slowing of disease progression on cUHDRS at 36 months (p=0.003) and 60% on TFC (p=0.033), highly statistically significant for a Phase 1/2
- FDA granted RMAT (first-ever for HD), Breakthrough Therapy, and Fast Track designations, multiple accelerated pathways
- Pivotal data comes from a relatively small Phase 1/2 trial (n=26 US + European cohort) vs external controls, not a randomized double-blind sham-controlled trial, weaker evidence standard
- Safety concerns around invasive neurosurgical delivery, requires MRI-guided infusion directly into the brain, which limits patient accessibility and carries procedural risks
- Durability beyond 3 years is unknown; gene therapy is permanent and cannot be removed if long-term safety issues emerge